

bs-1369R**[Primary Antibody]****MAP2 Rabbit pAb****Bioss**
ANTIBODIES

www.bioss.com.cn

sales@bioss.com.cn


techsupport@bioss.com.cn

400-901-9800


— DATASHEET —**Host:** Rabbit**Isotype:** IgG**Clonality:** Polyclonal**GeneID:** 4133**SWISS:** P11137**Target:** MAP2**Immunogen:** KLH conjugated synthetic peptide derived from human MAP2: 1-120/1827.**Purification:** affinity purified by Protein A**Concentration:** 1mg/ml**Storage:** 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.


Background: MAP2 is the major microtubule associated protein of brain tissue. There are three forms of MAP2; two are similarly sized with apparent molecular weights of 280 kDa (MAP2a and MAP2b) and the third with a lower molecular weight of 70 kDa (MAP2c). In the newborn rat brain, MAP2b and MAP2c are present, while MAP2a is absent. Between postnatal days 10 and 20, MAP2a appears. At the same time, the level of MAP2c drops by 10-fold. This change happens during the period when dendrite growth is completed and when neurons have reached their mature morphology. MAP2 is degraded by a Cathepsin D-like protease in the brain of aged rats. There is some indication that MAP2 is expressed at higher levels in some types of neurons than in other types. MAP2 is known to promote microtubule assembly and to form side-arms on microtubules. It also interacts with neurofilaments, actin, and other elements of the cytoskeleton.

Applications: WB (1:500-2000)**IHC-P** (1:100-500)**IHC-F** (1:100-500)**IF** (1:200-800)**Flow-Cyt** (1ug/Test)**Reactivity:** Human, Mouse, Rat**Predicted MW.:** 70/201 kDa**Subcellular Location:** Cytoplasm ,Nucleus**— VALIDATION IMAGES —**




Sample: Cerebrum (Mouse) Lysate at 40 ug
 Primary: Anti-MAP2 (bs-1369R) at 1/1000 dilution
 Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 201 kD
 Observed band size: 280 kD



Paraformaldehyde-fixed, paraffin embedded (Human brain glioma); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (MAP2) Polyclonal Antibody, Unconjugated (bs-1369R) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructions and DAB staining.



Paraformaldehyde-fixed, paraffin embedded (Rat brain); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (MAP2) Polyclonal Antibody, Unconjugated (bs-1369R) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructions and DAB staining.



Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

Paraformaldehyde-fixed, paraffin embedded (Mouse brain); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (MAP2) Polyclonal Antibody, Unconjugated (bs-1369R) at 1:400 overnight at 4°C, followed by a conjugated Goat Anti-Rabbit IgG antibody (bs-0295G-FITC) for 90 minutes, and DAPI for nuclei staining.

Tissue/cell: rat brain tissue;4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer (0.01M, pH 6.0), Boiling bathing for 15min; Blocking buffer (normal goat serum,C-0005) at 37°C for 20 min; Incubation: Anti-MAP2/MAP-2a.b.c Polyclonal Antibody, Unconjugated(bs-1369R) 1:200, overnight at 4°C; The secondary antibody was Goat Anti-Rabbit IgG, FITC conjugated (bs-0295G-FITC)used at 1:200 dilution for 40 minutes at 37°C. DAPI(5ug/ml,blue,C-0033) was used to stain the cell nuclei

The SH-SY5Y (H) cells were fixed with 4% PFA (10 min at r.t.) and then permeabilized with 90% ice-cold methanol for 20 min at -20°C,the cells then were incubated in 5%BSA to block non-specific protein-protein interactions (30 min at r.t.), followed by secondary antibody incubation for 40 min at room temperature. Primary Antibody (green):Rabbit Anti-MAP2 antibody (bs-1369R): 1 µg/10⁶ cells; Isotype Control (orange): Rabbit IgG (bs-0295P). Blank control (black): PBS. Acquisition of 20,000 events was performed.

— SELECTED CITATIONS —

- **[IF=13.281]** Yu Hei. et al. Multifunctional Immunoliposomes Enhance the Immunotherapeutic Effects of PD-L1 Antibodies against Melanoma by Reprogramming Immunosuppressive Tumor Microenvironment. 2021 Dec 16 IF,IHC ;Mouse. 34915595
- **[IF=11.092]** Yan Hu. et al. An ECM-Mimicking, Injectable, Viscoelastic Hydrogel for Treatment of Brain Lesions. ADV HEALTHC MATER. 2022 Nov;;2201594 IF ;Mouse. 36398536
- **[IF=5.878]** Lin Zhu. et al. Neuroprotective effects of salidroside on ageing hippocampal neurons and naturally ageing mice via the PI3K/Akt/TERT pathway. 2021 Aug 09 WB ;Rat. 34374127
- **[IF=6.291]** Hongmei Zhou. et al. Downregulation of beclin 1 restores arsenite-induced impaired autophagic flux by improving the lysosomal function in the brain. Ecotox Environ Safe. 2022 Jan;229:113066 IF ;Mouse. 34929507
- **[IF=5.753]** Chaohua Cong. et al. PAK4 suppresses motor neuron degeneration in hSOD1G93A - linked amyotrophic lateral sclerosis cell and rat models. 2021 Feb 21 IF,IHC ;Mouse. 33615605